Innophore GmbH

Innophore GmbH is a biotechnology company that provides a platform for enzyme and drug discovery through its proprietary Catalophore technology. Founded in 2017 in Graz, Austria, the company uses artificial intelligence and 3D point-cloud analysis to characterize protein binding sites rather than focusing on proteins alone. This methodology allows the company to conduct cavity-based searches across entire proteomes, offering capabilities that exceed traditional sequence or fold comparison methods. By transforming molecular structure into actionable data, Innophore supports research and development pipelines by identifying and optimizing protein candidates for applications in biotechnology, pharmaceuticals, and industrial processes.

The company's technology is utilized by global partners in sectors including healthcare, chemicals, and consumer products to accelerate R&D and improve safety. Innophore’s solutions enable clients to detect potential off-target interactions, reduce side effects, and optimize therapeutic or industrial enzymes more efficiently. The company gained significant industry recognition during the COVID-19 pandemic by rapidly identifying the SARS-CoV-2 main protease as a drug target. Innophore maintains collaborations with major technology partners, such as NVIDIA, to leverage advanced computational platforms like BioNeMo for large-scale structural modeling and drug discovery predictions, helping clients bring products to market with greater speed and precision.